How Eli Lilly’s GLP‑1 Strategy Drives 52‑Week Rally Amid Market Shifts
Explore why Eli Lilly’s GLP‑1 strategy and robust pipeline keep its stock soaring amid market turbulence.
2 minutes to read
ELI LILLY & CO
El Lilly Posts Q3 Profit Surge, Raises Full‑Year Sales Outlook on Mounjaro, Zepbound Momentum
El Lilly posts Q3 earnings jump and raises sales guidance, driven by Mounjaro & Zepbound demand, boosting confidence in its obesity‑diabetes pipeline.
2 minutes to read
How Eli Lilly’s $5 B Oncology Manufacturing Push & Breakthrough ADCs Outpace AI Stocks
Discover how Eli Lilly’s 79% response rate in ovarian cancer and $5B Virginia manufacturing hub propel it ahead of AI stocks and boost investor confidence in oncology and weight‑loss markets.
3 minutes to read